1248 Management’s Edwards Lifesciences EW Stock Holding History

1248 Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-16,200	Closed	-$1.27M	–	158
2025 Q2	$1.27M	Sell	16,200 -298	-2%	-$22.2K	0.47%	38
2025 Q1	$1.2M	Hold	16,498	–	–	0.51%	32
2024 Q4	$1.22M	Buy	+16,498	New	+$1.15M	0.53%	39

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

1248 Management's EW Position: Q3 2025 in Review

1248 Management sold out of Edwards Lifesciences (EW) in Q3 2025, closing a stake of 16,200 shares — an estimated $1.27M sold.

1248 Management first reported a position in EW in Q4 2024 and held it in 3 quarters. The position peaked at $1.27M in Q2 2025. 1,254 funds tracked by Wall St. Rank hold EW as of Q3 2025.

1248 Management reported no remaining Edwards Lifesciences position as of Q3 2025 after selling out during the quarter.
1248 Management sold 16,200 Edwards Lifesciences shares in Q3 2025, an estimated $1.27M.
1248 Management first reported a position in Edwards Lifesciences in Q4 2024 and held it in 3 quarters.
1248 Management's Edwards Lifesciences position peaked at $1.27M in Q2 2025.
1,254 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2025.

Based on 1248 Management's 13F filing for Q3 2025, filed 14 Nov 2025.